CD19 and hematologic disorder: Promising immunotherapy approaches for CD19-positive hematological malignancies include the adoptive transfer of T cells that are genetically modified to express CD19-specific chimeric antigens receptors (CARs) or the infusion of bispecific antibodies that redirect resident T cells to CD197, 8, 9, 10, 11, 12, 13, 14, 15.